Compare BioNano Genomics Inc (BNGO) vs EPR Properties (EPR) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
BioNano Genomics Inc vs EPR Properties — how do they compare? BioNano Genomics Inc trades at $1.15 (market cap $13.20M), while EPR Properties trades at $60.14 (market cap $4.56B). The key difference: EPR Properties is far larger — about 345.5× BioNano Genomics Inc's market cap, and EPR Properties pays a 6.25% dividend while BioNano Genomics Inc pays none. Which is the better fit depends on your goals.
| BNGO | EPR | |
|---|---|---|
Market Cap | $13.20M | $4.56B |
Sector | Health | Real Estate |
52-Week High | $4.92 | $60.81 |
52-Week Low | $1.09 | $48.71 |
Enterprise Value | $15.81M | $7.62B |
Dividend Yield | — | 6.25% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Bionano Genomics (BNGO) trades at $1.17, down 2.5% today, but maintains a bullish technical signal with strong moving average support. The company shows improving fundamentals with revenue stabilizing around $29M annually and narrowing losses, though it remains unprofitable with a -109.95% net margin. Recent positive developments include debt retirement and growing adoption of optical genome mapping technology.
BNGO presents a high-risk, high-reward opportunity with analyst consensus leaning bullish (57% buy ratings). The stock trades at attractive valuation multiples (P/S 0.31, P/B 0.36) but faces execution risks in achieving profitability. Key catalysts include continued technology adoption and potential margin improvement, while persistent losses and competitive pressures remain concerns.
EPR Properties trades at $59.81, up 0.32% today, with a bullish technical signal from moving averages and strong fundamentals including a 39.93% net income margin and consistent dividend payments. Recent earnings show mixed results with a Q1 2026 miss but previous quarters beating expectations. The company maintains robust cash flow from operations of $421 million in 2025 and high portfolio occupancy.
Outlook remains positive with a consensus price target of $63.00, though risks include reliance on experiential real estate and market sensitivity. The stock offers a compelling blend of income and growth, supported by analyst buy ratings and recent acquisitions like the Six Flags park deal.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About BioNano Genomics Inc
Bionano Genomics Inc is a life sciences instrumentation company in the genome analysis space. It is engaged in the development and marketing of the Saphyr system, a platform for ultra-sensitive and ultra-specific structural variation detection that enables researchers and clinicians to accelerate the search for new diagnostics and therapeutic targets and to streamline the study of changes in chromosomes.
Read more on BNGO →About EPR Properties
EPR Properties is a REIT specializing in experiential real estate, including movie theaters and leisure destinations like ski resorts and water parks across the US and Canada.
Read more on EPR →
